TNFRSF17 and Miyoshi myopathy: A previously conducted clinical trial by Cohen AD et al. concluded that BCMA-specific CAR containing D3ζ and 4-1BB signaling domain (CART-BCMA) infusions are clinically active with or without lymphodepleting chemotherapy in pretreated patients with MM [11].